Patents Assigned to Beigene, Ltd.
  • Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor
    Patent number: 12582604
    Abstract: Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-1-yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: March 24, 2026
    Assignee: BeiGene, Ltd.
    Inventors: Guoliang Zhang, Changyou Zhou, Huangbin Sun
  • Cyclic dinucleotides as sting agonists
    Patent number: 12435104
    Abstract: Disclosed herein are cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING agonists, and a pharmaceutical composition comprising the same. Also disclosed herein is the process for synthesis and to uses of such cyclic di-nucleotide compounds in various diseases including cancer, HIV infection and HBV infection.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: October 7, 2025
    Assignee: BeiGene, Ltd.
    Inventors: Jing Li, Zhiwei Wang, Lina Gu, Sanjia Xu
  • BCL-2 Inhibitor
    Publication number: 20250270210
    Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.
    Type: Application
    Filed: January 23, 2025
    Publication date: August 28, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Hai Xue, Yunhang Guo, Zhiwei Wang
  • 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF
    Publication number: 20250236610
    Abstract: Disclosed herein is 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g.
    Type: Application
    Filed: April 11, 2025
    Publication date: July 24, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Sanjia XU, Jing LI, Zhiwei WANG
  • HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20250221996
    Abstract: Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.
    Type: Application
    Filed: January 6, 2025
    Publication date: July 10, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Ce WANG, Chao YU, Hao YUAN, Xiaoyu LI, Zhiwei WANG, Hanzi SUN
  • Anti-FGFR2b Antibodies, Conjugates and Methods of Use
    Publication number: 20250222125
    Abstract: Anti-FGFR2b antibodies and antigen-binding fragments thereof are provided herein, as are immunoconjugates comprising the same, and compositions comprising the antibodies and immunoconjugates. Also provided are methods of making and using the antibodies and immunoconjugates, such as to treat an FGFR2b-related disease or disorder. The antibodies of the disclosure bind to human FGFR2b and can block the interaction between the KGF ligand and FGFR2b.
    Type: Application
    Filed: January 3, 2025
    Publication date: July 10, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Charng-Sheng TSAI, Mei-Hsuan TSAI, Xiaodong WEI, Mengran QIAN, Qun WANG, Ruyue JI, Jie PAN, Yibin XU, Maomao HE, Zewei WANG, Wei LUO, Bing LI, Liming WU
  • DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20250195513
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: December 6, 2024
    Publication date: June 19, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Huaqing LIU, Dongqing SUN, Zhiwei WANG
  • HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20250163047
    Abstract: Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
    Type: Application
    Filed: August 7, 2024
    Publication date: May 22, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Guoliang Zhang, Jianzhuang Miao, Hanzi Sun, Zhikun Ni, Zhi Zhang, Ce Wang
  • Small Molecule IL-17A Modulators
    Publication number: 20250154138
    Abstract: Disclosed herein are fused bi-cyclic compounds used as Small Molecule IL-17A Modulators. Disclosed herein is the use of these Small Molecule IL-17A Modulators for the use of decreasing IL-17 activity by inhibition, and the use of such compounds for the use in the treatment of autoimmune diseases or inflammatory diseases.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 15, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Hai Xue, Yunhang Guo, Si Chen, Zhiwei Wang
  • ANTI-GPC3 AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
    Publication number: 20250154279
    Abstract: The present disclosure provides for the antibodies or antigen-binding fragment thereof that specifically binds human CD137, multispecific antibodies and antigen-binding fragments thereof that specifically bind to human GPC3 and CD137, a pharmaceutical composition comprising said antibody, and use of the antibody, multispecific antibody or the composition for treating a disease, such as cancer.
    Type: Application
    Filed: November 20, 2024
    Publication date: May 15, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Liang QU, Liu XUE, Ruyue JI, Xi YUAN, Zhuo LI, Jie LI, Jian SUN
  • Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
    Publication number: 20250136586
    Abstract: This disclosure provides compounds containing 7-(pyrimidin-4-yl)quinolin-4(1H)-one structure, the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of various diseases including cancer.
    Type: Application
    Filed: October 25, 2024
    Publication date: May 1, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Jing LI, Wenqing Xu, Zhiwei Wang
  • Bcl-2 inhibitor
    Patent number: 12286430
    Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 29, 2025
    Assignee: BeiGene, Ltd.
    Inventors: Hai Xue, Yunhang Guo, Zhiwei Wang
  • Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist
    Patent number: 12281119
    Abstract: Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: April 22, 2025
    Assignee: BEIGENE, LTD.
    Inventors: Guoliang Zhang, Jianzhuang Miao, Changyou Zhou, Gang Chen, Jing Li
  • ANTI-CCR8 ANTIBODIES AND METHODS OF USE
    Publication number: 20250115671
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human CCR8, a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer.
    Type: Application
    Filed: October 29, 2024
    Publication date: April 10, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Ming FANG, Liu XUE, Hanzi SUN, Xiaoyan TANG, Ming JIANG, Xitao WANG, Yun CHEN, Chichi HUANG, Wenjie WANG, Jing ZHANG, Wenbo JIANG
  • HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20250101028
    Abstract: Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
    Type: Application
    Filed: September 19, 2024
    Publication date: March 27, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Chao YU, Jie CHEN, Hanzi SUN, Huaqing LIU, Ce WANG, Zhiwei WANG
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20250099607
    Abstract: Antibody-drug conjugate compounds comprising a linker and methods of using such compounds are provided.
    Type: Application
    Filed: December 6, 2024
    Publication date: March 27, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Charng-Sheng Tsai, Mei-Hsuan Tsai, Xiaodong Wei
  • HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20250066372
    Abstract: Provided herein are compounds having the following structure: or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof, wherein the substituents are as defined herein compositions comprising an effective amount of a compound, and methods for inhibiting activity of cyclin-dependent kinases.
    Type: Application
    Filed: November 1, 2024
    Publication date: February 27, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Chao YU, Hanzi SUN, Ce WANG, Zhiwei WANG
  • POLYMORPH FORMS OF A 5H-PYRROLO[2,3-b]PYRAZINE DERIVATIVE, METHODS OF PREPARATION, AND USES THEREFORE
    Publication number: 20250042909
    Abstract: The present invention relates to salts of a HPK1 inhibitor (referred to as “Compound A” hereinafter), preferably citrate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.
    Type: Application
    Filed: October 23, 2024
    Publication date: February 6, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Hui Chen, Sanjia Xu, Jing Li, Zhengming Du, Zhiwei Wang
  • BCL-XL INHIBITORS
    Publication number: 20250034128
    Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-xL and treating a disease associated with the undesirable Bcl-xL activity (Bcl-xL related diseases), a method of using the compounds disclosed herein for treating tumor or cancer, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 30, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Ling Qin, Yunhang Guo, Zhiwei Wang
  • Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors
    Publication number: 20250026766
    Abstract: The present invention relates to compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including cancers.
    Type: Application
    Filed: July 2, 2024
    Publication date: January 23, 2025
    Applicant: BeiGene, Ltd.
    Inventors: Jing Li, Wenqing Xu, Zhiwei Wang